May 20, 2026
Subsequent Treatment Strategies in RCC:How Relapse Timing Guides Clinical Decisions
May 20, 2026
Optimizing Duration of Immuno-Therapyin Metastatic Renal Cell Carcinoma– When to Treat, Paus or Stop
May 20, 2026
Overview of Nordic Clinical Trials
May 20, 2026
Adjuvant Treatment in RCC – Perspectives in the Nordics
May 20, 2026
What Can Patients Do to Improve Outcomes?
May 20, 2026
Cytoreductive Nephrectomy and Secondary Nephrectomy. To do or not and what is the Evidence. 4
May 20, 2026
Navigating the unclear in Non-clear cell RCC. 4
May 20, 2026
Curative approach in oligometastatic disease-Patient Cases.
May 14, 2026
Cytoreductive nephrectomy in advanced RCC – Clinical Praxis in Sweden
May 14, 2026
Management of specific drug toxicities The Immunotoxicity Clinic.
May 14, 2026
Optimal treatment for patients in favorable IMDCs risk groups
April 17, 2026
How to Optimize the Treatment in First Line RCC
April 17, 2026
Cabozantinib for the treament of Neuroendocrine Tumors
September 5, 2025
Patient cases TKI-biverkningar
May 20, 2025
Tumor Immune MicroEnvironment (TIME) in metastatic Renal Cell Carcinoma: Prognostic Biomarkers and Targeted Treatment
April 7, 2025
Prostate Cancer Screening in Europe: Current Status and Future Directions
March 25, 2025
Adjuvant treatment in RCC Updated KEYNOTE-564 OS data Consideration of side effects and subgroups of patients
March 25, 2025
Optimizing systemic treatment sequencing for renal cell carcinoma beyond adjuvant therapy
March 25, 2025
Small renal masses – when and how to treat?Part 3: SBRT Treatment.
March 25, 2025
Small renal masses – when and how to treat?Part 2: Ablation of small renal masses.
March 25, 2025
Small renal masses – when and how to treat?Part 1: Nephron-sparing surgery.
March 25, 2025
Adjuvant therapy for RCC: Is the risk worth the reward?
November 24, 2024
How to optimize Cabozantinib
June 5, 2024
Patient cases Case 1: FH deficient RCC Case 2: Unclassified RCC
December 1, 2023
Non-drug options in oligometastatic RCC
December 1, 2023
Approaches to treatment of oligoprogressive disease, Patient case and discussion
December 1, 2023
nccRCC – Should we change our practice?
December 1, 2023
Cytoreductive nephrectomy in advanced RCC – Praxis in Norway
December 1, 2023
To cut or not to cut: The role of cytoreductive nephrectomy in advanced RCC
December 1, 2023
Cytoreductive Nephrectomy in advanced RCC – Praxis in Denmark
December 1, 2023
Adjuvant treatment in RCC – Status in the Nordics – Sweden
December 1, 2023
Adjuvant treatment in RCC – Status in the Nordics – Norway
December 1, 2023
Adjuvant treatment in RCC – Status in the Nordics – Denmark
December 1, 2023
Adjuvant treatment in RCC
November 10, 2022
QoL in mRCC clinical trials
August 2, 2022
Case experiences with combination therapy with cabozantinib + nivolumab as first-line treatment
August 2, 2022
Long-Term effectiveness results of CheckMate-9ER
August 2, 2022
Timing of the treatment and patient stratification
August 2, 2022
First-line combination treatments available for renal cell carcinoma
August 2, 2022
Quality of life and Patient-Reported Outcome Measures
October 12, 2021
Nivolumab + Cabozantinib for the treatment of advanced Renal-Cell Carcinoma in 1L
September 9, 2021
Rationale for combinations with CPI
April 29, 2021
How can we help the patient to stay on treatment
March 1, 2021